Drugs / Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01209871 | Feb 2015 → Apr 2025 | lymphoplasmacytic lymphoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous Lymphoma Immunoglobulin-derived scFv-chemokine DNA Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01209871 ↗ |
| Action | Deplete | “Vaccines made from a person's cancer cells may help the body build an effective immune response to kill cancer cells.” NCT01209871 ↗ |
| Modality | Vaccine | “next-generation DNA vaccine” PMID 29439670 ↗ Feb 2018 |